1. Novartis' Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income; 2. The acquisition of Anthos Therapeutics and strategic investments in R&D support Novartis' position as a leader in innovative medicines; 3. Novartis' strong free cash flow generation, supportive dividend yield, and ongoing buyback make it an attractive investment.